Mylan’s Generic Version of Biogen’s MS Drug Gets FDA Approval Post author:Sam Post published:August 20, 2020 Post category:Devices & Diagnostics Letter Mylan has launched the product in 120mg and 240mg delayed-release capsule forms. Source: Devices & Diagnostics Letter You Might Also Like Ridgeback Biotherapeutics to Launch Two Trials of Its COVID-19 Antiviral June 22, 2020 Keytruda Approved in China for Esophageal Squamous Cell Carcinoma June 22, 2020 UK Review Finds Better Device Data Might Prevent PIP-Type Safety Scares April 7, 2016